Loading...
Market
What will be the market share of KarXT among schizophrenia treatments by December 31, 2025?
2
Resolution / Starting Odds
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Market research reports and sales data
Story
KarXT: New Drug to Revolutionize Schizophrenia Treatment Pending FDA Approval in September 2024
Sep 19, 2024, 07:08 PM
A new experimental drug, KarXT, is set to potentially revolutionize the treatment of schizophrenia, a condition often referred to as the 'cancer of psychiatry.' If approved by the US Food and Drug Administration (FDA) later this month, KarXT will be the first truly novel treatment for schizophrenia in over seven decades. This twice-daily pill offers hope to millions of individuals who suffer from the condition and are frequently marginalized in society. The approval of KarXT in September 2024 could mark a significant advancement in the field of psychiatry and mental health treatment.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Yes • 50%
No • 50%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative impact • 25%
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%